Abstract
Alternatively spliced variants of fibronectin (FN) containing exons EIIIA and EIIIB are expressed around newly forming vessels in development and disease but are downregulated in mature vasculature. The sequences and patterns of expression of these splice variants are highly conserved among vertebrates, suggestive of their biological importance; however the functions of EIIIA and EIIIB-containing FNs are unknown. To understand the role(s) of these splice variants, we deleted both EIIIA and EIIIB exons from the FN gene and observed embryonic lethality with incomplete penetrance by embryonic day 10.5. Deletion of both EIIIA and EIIIB exons did not affect synthesis or cell surface deposition of FN, indicating that embryonic lethality was due specifically to the absence of EIIIA and EIIIB exons from FN. EIIIA/EIIIB double-null embryos displayed multiple embryonic cardiovascular defects, including vascular hemorrhage, failure of remodeling embryonic and yolk sac vasculature, defective placental angiogenesis and heart defects. In addition, we observed defects in coverage and association with dorsal aortae of alpha-smooth-muscle-actin-positive cells. Our studies indicate that the presence or absence of EIIIA and EIIIB exons alters the function of FN and demonstrate the requirement for these alternatively spliced exons in cardiovascular development.
Keywords: cardiovascular development, fibronectin, alternative splicing
Introduction
Organismal development, whether in invertebrates or vertebrates, involves extensive migration of cells and germ layers to generate the animal body plan. These migrations take place through a variety of adhesive cell-cell and cell-matrix interactions. Extracellular matrix provides both adhesive and signaling platforms for the migrating cells, (reviewed in (Hynes, 1990; Hynes, 2002; Lauffenburger and Horwitz, 1996; Schwartz et al., 1995). While many extracellular matrix molecules such as laminins and collagens appeared early in evolution and are conserved from fly to human, fibronectin (FN) has been found only in vertebrates and its appearance in evolution correlates with the appearance of organisms with endothelial cell-lined vasculature (Hynes and Zhao, 2000; Whittaker et al., 2006). Consistent with this observation, FN is essential for early embryonic development; mice lacking FN die by embryonic day 9.5 with severe cardiovascular defects, including malformed or absent embryonic vessels and heart (George et al., 1993; Georges-Labouesse et al., 1996).
FN is a complex, alternatively spliced multidomain protein. FN domains are classified into type I (twelve domains), type II (two domains) and type III (fifteen-seventeen domains) FN repeats. In addition, FN is alternatively spliced at three regions which can be included or excluded, either completely (EIIIA, EIIIB, both type III repeats) or partially (the V region), generating up to 12 different variants in rodents and 20 in humans (Hynes, 1990; Kornblihtt et al., 1985; Kornblihtt et al., 1984a; Pankov and Yamada, 2002; Schwarzbauer et al., 1987). These splice variants are differentially expressed in development and disease, both spatially and temporally (ffrench-Constant and Hynes, 1989; ffrench-Constant et al., 1989; Peters et al., 1996; Peters and Hynes, 1996; Tan et al., 2004). The importance of some repeats is well known; for example, the 9th and 10th type III repeats as well as the V region function in cell adhesion to cell-surface integrins (Aota et al., 1991; Guan and Hynes, 1990; Hynes, 1990; Pankov and Yamada, 2002), the 13th type III repeat is important for binding to proteoglycans and for assembly of actin stress fibers (Bloom et al., 1999; Wierzbicka-Patynowski and Schwarzbauer, 2003); the functions of other repeats are not understood. While being distinct from each other in sequence, all of the FN repeats are conserved through evolution, suggesting importance of each of these repeats for the functions of FN. The alternative splicing of FN introduces another level of complexity and raises questions such as whether the inclusion or exclusion of the alternatively spliced domains alters the functions of FN and the biological consequences of their presence or absence.
Alternative splicing of EIIIA and EIIIB exons of FN is dynamically regulated in vivo. These splice variants are expressed at very low levels or not at all in the adult (Peters et al., 1996). However, during embryogenesis, both EIIIA and EIIIB exons become included into cellular FN (Peters and Hynes, 1996) and, in adults, these splice variants appear during pathological processes requiring growth and/or remodeling of the existing vasculature (Carnemolla et al., 1989; Glukhova et al., 1989; Peters et al., 1988; Shekhonin et al., 1990; Trachsel et al., 2006).
There is a strong correlation between the expression of EIIIA and EIIIB and the presence of vascular remodeling. During embryonic development, EIIIA and EIIIB are expressed around embryonic vessels (ffrench-Constant and Hynes, 1989; Peters and Hynes, 1996); but this expression ceases when the process of vascular development is complete (ffrench-Constant and Hynes, 1989; Peters et al., 1996). In adults, there is little or no detectable expression of EIIIA and EIIIB around quiescent vasculature in either mouse or human. However, during pathological angiogenesis, for example in the process of tumor development, these exons become included into FN. In fact, all human and murine tumors that have been examined for the presence of these splice variants show their abundant expression in the extracellular matrix surrounding tumor vessels (references in (Astrof et al., 2004; Castellani et al., 2002; Oyama et al., 1989). This correlation is so striking that it has led to the development of anti-EIIIB antibody as a tumor-targeting and a tumor-imaging reagent in mice and humans (Borsi et al., 2002; Kaspar et al., 2006; Nilsson et al., 2001).
Other pathological processes during which EIIIA and EIIIB are included in the FN are wound healing, atherosclerosis, and myocardial infarction, all of which require vascular remodeling (ffrench-Constant et al., 1989; Matter et al., 2004; Shekhonin et al., 1990). In spite of their high degree of sequence conservation among vertebrate species and the evolutionarily conserved regulation of their expression patterns, the functions of these splice variants have remained a mystery for nearly two decades since their original discovery.
A number of in vitro studies have claimed various, often discordant (from no effect to some) effects of inclusion of EIIIA or EIIIB exons on cell attachment, migration, proliferation, cell survival, matrix assembly, or expression of smooth muscle α actin (Chen and Culp, 1996; Guan et al., 1990; Hashimoto-Uoshima et al., 1997; Manabe et al., 1999; Serini et al., 1998; Xia and Culp, 1994). However, in vivo, the individual deletion of EIIIA or EIIIB has not given much insight into the possible functions of these splice variants. EIIIA-null or EIIIB-null mice are viable and fertile, and physiological angiogenesis such as embryonic vascular development and retinal angiogenesis after birth proceeded apparently normally in these mice (Astrof et al., 2004; Fukuda et al., 2002; Muro et al., 2003; Tan et al., 2004). Tumor growth and angiogenesis examined in the transgenic Rip-Tag tumor model were not significantly affected by the absence of either of the splice variants. Furthermore, contrary to expectations, the development of αSMA-positive cells was not affected (Astrof et al., 2004). However the absence of EIIIA was mildly protective in an atherosclerosis model (Tan et al., 2004). In one study, a delay in cutaneous wound healing in EIIIA-null mice was noted (Muro et al., 2003), but this effect was not replicated in another study ( Tan et al., 2004). Interestingly, a possible effect of EIIIB on FN matrix assembly and proliferation was observed in EIIIB-null MEFs in vitro and recombinant EIIIB-positive FN incorporated somewhat more efficiently into ECM (Fukuda et al., 2002; Guan et al., 1990), suggesting a possible role for EIIIB in FN matrix assembly.
Since the EIIIA and EIIIB splice variants are highly conserved in sequence and expression pattern among species, we reasoned that simultaneous deletion of both of these exons might allow us to understand their function(s). Indeed, the absence of both EIIIA and EIIIB was embryonic lethal in the majority of embryos leading to severe cardiovascular defects. Here we report the phenotypes of the EIIIA/EIIIB_double-null embryos and the possible functions of EIIIA and EIIIB in vascular development.
Materials and Methods
Generation of EIIIA and EIIIB double-null mice
EIIIB-null ES cells were generated from EIIIB-null mice (Fukuda et al, 2002) by isolating EIIIB-null zygotes. Zygotes were cultured in KSOM medium (Chemicon, Temecula, CA) for three days until blastocyst stage and then plated on a monolayer of mouse embryo fibroblasts (MEFs) in ES cell medium containing 1000 U/ml LIF (Chemicon) and 50 μM MEK inhibitor PD98059 (Cell Signalling Technology, Danvers, MA) as described (Nagy A, 2003). Following four days of incubation, ES cell colonies were picked, trypsinized and plated on a monolayer of MEFs. Two independent clones of EIIIB-null ES cells were isolated and tested for germline transmission. One of the clones, B8, was selected for further targeting to generate the EIIIA-null allele. The EIIIA-null allele was generated as described (Tan et al., 2004) using a targeting construct generously provided by Elizabeth George, and subsequent transfection of the targeted ES cells with Cre recombinase-encoding plasmid, pMC-Cre (Gu et al., 1993). Southern blots were performed using restriction enzymes EcoRI, HindIII, and BamHI and probe 2 (Tan et al., 2004) as well as restriction enzyme AvrII with probes 2 and sub44 (Fig. 2). Correctly targeted ES cell clones were injected into blastocysts derived from FVB/NJ mice and chimeric mice were mated with C57BL6/J wild-type mice. The progeny were genotyped using primers 5′-GTA CGT AAC CAA TGC TCG GT – 3′ (primer 4) and 5′-CAC AGA CTA TTC CAT CCT AGA GAT AG -3′ (primer 5) to detect EIIIA-null (1233 bp) and wild-type (2092 bp) alleles and 5′-GCA CAC TTT GGA GGC CTG TCT TAG – 3′ (primer 1), 5′ – GAA AGC AAG CCA TGG GGG GCC TGG CC – 3′ (primer 2), 5′-CCT GGC CTG GAG TAC AAC GTC AGT G – 3′ (primer 3), to detect EIIIB-null (818 bp) and wild-type (616 bp; 2099 bp wild type band was not detected under the PCR conditions used) alleles. Genomic PCR primers described previously (Fukuda et al., 2002; Tan et al., 2004) were also used to genotype EIIIA-null and EIIIB-null alleles. The PCR results were confirmed by Southern blot using AvrII restriction enzyme and probe 2 (see Figure 2C).
Quantification of FN message and protein levels
RT-PCR
RNA from e9.5 embryos was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. RNA was treated with RNase-free DNase, repurified and used for reverse transcription. The presence or absence of EIIIA or EIIIB exons in FN mRNA was detected as described (Astrof et al., 2004). To quantify FN mRNA levels, quantitative real-time PCR was performed using primers 5′-CCT CTC TGG AAG AAG TGG TCC-3′ and 5′-GAC GTT GTA CTC CAG GCC AG-3′ lying within the 7b (III7b) exon, primers 5′-CTC CCA CGG ATC TGC GAT TC-3′ and 5′-GGT TGG TCA GCT CGA TGG AC-3′ lying within the III8a exon and primers 5′-GTT CAG TCA GGT GAC ACC CAC-3′ and 5′-CCT GTC TTC TCT TTC GGG TTC-3′ lying within the III12a exon. RNA levels of mouse GAPDH served as controls. Incorporation of SYBR green into double-stranded PCR products was monitored using Biorad iCycler.
Western Blotting
Wild-type, heterozygous and null embryos were isolated at e9.5 or e14.5. Trunks of e9.5 and heads of e14.5 embryos were lysed as described (Senger et al., 1983). Briefly, frozen embryos were resuspended in 500 μl of SDS lysis buffer using 27-gauge needle. The lysis buffer contained 0.1 M Tris-HCl pH8.0, 0.2% SDS, protease inhibitors (one complete mini tablet (Roche, Basel, Switzerland) per 7 ml) and 2mM NEM, 4mM PMSF, 5mM EDTA. The lysates were boiled for 10 min and 140 mM β-mercaptoethanol was then added. Lysates were used without centrifugation. 40 μl of each lysate were resolved on SDS-PAGE gel (5% resolving, 3% stacking), and the rest was stored at −80°C. Rabbit polyclonal antibody 297.1 diluted 1:4000 was used to detect total (t) FN, goat polyclonal antibody 153.1 was used to detect EIIIA (Peters et al., 1996; Peters and Hynes, 1996) and mouse monoclonal antibody SAP.4G5, diluted 1:5000 was used to detect β-tubulin 1 (T7816, Sigma, St. Louis, MO). The staining was detected using affinity-purified donkey anti-rabbit, donkey anti-goat and donkey anti-mouse antibodies conjugated to horseradish peroxidase (Jackson Immunoresearch, West Grove, PA) diluted 1:3000 and Western Lightning kit (Perkin Elmer, Waltham, MA), and quantified using a Storm phosphorimager. Intensity of FN bands was normalized to that of β-tubulin bands.
Metabolic Labeling
Wild-type, heterozygous and null MEFs were isolated from e14.5 embryos as described (Nagy, 2003). 5×105 cells were plated on 60-mm dishes for 24 hours and labeled using 35S-Methionine/Cysteine (NEN, Waltham, MA) as described (Senger et al., 1983). Briefly, cells were incubated with 200 μCi in 1 ml of medium for two hours, supernatants were collected at 60, 80, 100 and 120 min, and resolved using 5% SDS-PAGE. To assay incorporation of FN into the cell matrix, cells were labeled for two hours, washed, and incubated in label-free medium for 24 hours. Cells were then lysed and FN was immunoprecipitated using 297.1 antibody and protein G agarose.
Immunohistochemistry and Immunofluorescence
Embryos were isolated at e9.5 or e10.5, fixed with 3.75% formalin at 4°C overnight and dehydrated through a methanol series (25%, 50%, 75%). They were then incubated with 6% H2O2 in methanol for four hours, re-hydrated through the methanol series and used for whole-mount staining with anti-Pecam 1 antibody (Pharmingen, Rockville, MD). Embryos were first incubated with blocking solution (PBS, 0.1% Triton-X-100 and 10% goat serum) at 4°C overnight, then with the anti-Pecam 1, diluted 1:100 in the blocking solution, also 4°C overnight. Embryos were then washed with PBS containing 0.1% Triton-X-100 overnight and incubated with affinity-purified donkey anti-rat secondary antibody conjugated to horseradish peroxidase (Jackson Immunoresearch) at 4°C overnight. After washing, the embryos were developed using DAB kit (Vector, Burlingame, CA). Embryos were then embedded into histogel (VWR, West Chester, PA), fixed with 3.75% formalin at 4°C overnight and processed for histology into paraffin blocks. To stain for αSMA, sections were boiled in 10mM citric acid pH 6.0 for 10 min, incubated with blocking solution containing PBS, 0.05% Tween-20 and 10% donkey serum and then with alkaline-phosphatase-conjugated antibody to αSMA (A5691, Sigma) in blocking solution. After overnight incubation at 25°C, sections were washed and stained using NBT/BCIP solution (Roche). For detection of EIIIA, EIIIB and tFN, embryos were fixed in Zn fixative (BD Pharmingen) for 48 hours at room temperature, processed for paraffin embedding and sectioned. Sections were stained using 297.1 antibody to tFN (1:1000), purified rabbit polyclonal antibody 264.1 diluted to 25 ng/ml to detect EIIIB exon, and purified goat polyclonal antibody 153.1 diluted to 140 ng/ml to detect EIIIA exon (Astrof et al., 2004). PBS containing 0.05% Tween-20 and 3% chicken ovalbumin was used as blocking solution and diluent. Staining was developed using secondary antibodies conjugated to horseradish peroxidase (described above) diluted 1:200 and DAB kit. Placentae were fixed in 3.75% formalin at 4°C overnight, processed for paraffin embedding and sectioned. Sections were either stained with hematoxylin and eosin or with rabbit polyclonal anti-laminin-1 antibody (L9393, Sigma) diluted 1:100 followed by affinity-purified donkey anti-rabbit antibody conjugated to alkaline phosphatase (Jackson Immunoresearch) and developed using NBT/BCIP. All sections were counterstained with methyl green and observed using an Axiophot microscope. Immunofluorescence studies to detect tFN, EIIIA and EIIIB splice variants were performed as described (Peters and Hynes, 1996).
Results
Expression of EIIIA and EIIIB splice variants during embryonic development
The expression patterns of EIIIA and EIIIB splice variants have been extensively studied previously (ffrench-Constant and Hynes, 1989; Peters et al., 1996; Peters and Hynes, 1996), however, we re-examined embryonic expression of these splice variants in selected embryonic tissues at e10.5, using limiting amounts of antibodies to detect any possible differential expression. To our surprise, not all embryonic and extra-embryonic vessels stained well with antibodies to tFN, EIIIA or EIIIB. In placental labyrinth, embryonic vessels located closer to the edge but not those located closer to the giant-cell trophoblast layer expressed FNs; maternal vessels did not detectably express FNs within the labyrinth (Fig. 1A–D). Interestingly, within the e10.5 embryo, FN and its splice variants were highly enriched around dorsal aortae and pharyngeal arch arteries but were expressed either at very low levels or not at all around anterior cardinal veins (Fig. 1E–H). Finally, in accord with previous studies (ffrench-Constant and Hynes, 1989; Peters and Hynes, 1996), we found expression of EIIIA and EIIIB around endocardial and cushion cells of the heart (Fig. 1I–K). This pattern of expression suggested that EIIIA and EIIIB splice variants might be important for vascularization of placenta, the development of dorsal aortae and cardiac cushions. To examine the role of EIIIA and EIIIB splice variants in embryonic cardiovascular development, we deleted both EIIIA and EIIIB exons from the FN locus.
Generation of EIIIA and EIIIB double-null animals
EIIIA and EIIIB exons of FN are separated by about 10 kb of sequence in the mouse genome, thus precluding the possibility of obtaining EIIIA/EIIIB double-null mice through mating of EIIIA-null and EIIIB-null animals. To obtain the double-null mice, we isolated EIIIB-null male ES cells of a mixed 129P2/C57BL6/J background from EIIIB-null zygotes and used the targeting construct described previously for the generation of the EIIIA-null allele (Tan et al, 2004) to delete the EIIIA sequence in these cells. Following sequence-specific recombination, the floxed EIIIA allele is inserted such that the loxP sites in the EIIIA and EIIIB loci point toward each other, suggesting that treatment with Cre recombinase might result in the inversion of the region. Figure 2A shows the wild-type and the EIIIA-null genomic loci, containing loxP sites in place of EIIIA and EIIIB exons, in correct and in inverted orientations. We performed five Southern blot experiments using four different restriction enzymes and two different probes to show that the EIIIA locus is targeted correctly (Fig. 2B (a–e)) and that the region between the EIIIA and EIIIB exons is positioned in the correct orientation with respect to FN (Fig. 2B (c–e)). The targeted EIIIA−EIIIB−/EIIIA+EIIIB− ES cells were then injected into FVB/NJ wild-type blastocysts and the resulting chimeric mice were mated to wild-type C57BL6/J females. We verified the transmission of the EIIIA−EIIIB− allele using Southern blotting (data not shown) and intercrossed EIIIA−EIIIB−/EIIIA+EIIIB+ mice to obtain e9.5 embryos, which were then used to verify the absence of EIIIA and EIIIB sequences in the FN DNA, mRNA and protein of the double-null embryos (Fig. 2C, D and Fig. 3). Our data indicate that, indeed, the double-null embryos lacked both EIIIA and EIIIB exons (Fig. 2C and Fig. 3) and that the deletion of both of these exons did not compromise the expression of FN mRNA (Figs. 2D) and protein (Figs. 2C and Fig. 3), nor the deposition of FN into the matrix (Fig. 2E, Fig. S1 and Table S1).
Interbreeding of EIIIA−EIIIB−/EIIIA+EIIIB+ mice (mixed C57BL6/J and 129P2 background) produced only eighteen percent of the expected number of double-null adults (Table 1), suggesting that the absence of both EIIIA and EIIIB is embryonic lethal with about 80% penetrance. Indeed, fifty percent of e9.5 and eighty percent of e10.5 double-null embryos showed severe cardiovascular defects (Fig. 4), and were absorbed by e11.0 (Table 1 and data not shown). Interestingly, the ability to survive in the absence of EIIIA and EIIIB had a statistically significant genetic background component (Table 1). Intercrosses of double-heterozygous mice, backcrossed six times to 129S4 strain, did not produce any live progeny (fifty seven live mice were examined, representing nine litters), while about 50% of the expected number of the double-null mice were born from EIIIA−EIIIB−/EIIIA+EIIIB+ mice backcrossed six times to C57BL6/J strain (thirty three live mice were examined, representing eight litters). The partial viability of EIIIA/EIIIB-double null mice bred to C57BL6/J as opposed to 129S4 background is consistent with the observation that the phenotype of FN-null mice is milder on C57BL6/J than on 129S4 strain (George et al., 1997; Astrof et al, 2007).
Table 1.
Genotype | Age | ||
---|---|---|---|
Wild type | Het | Null | |
88 | 145 | 12 | Adult (129S4/C57BL6/J mixed) |
18 | 39 | 0 | Adult (129S4)* |
10 | 19 | 4 | Adult (C57BL6/J)* |
19 (1) | 44 (3) | 26 (12) | e 9.5(129S4/C57BL6/J mixed) |
15 (1) | 43 (4) | 16 (13) | e 10.5(129S4/C57BL6/J mixed) |
These distributions are statistically different: p=0.002, χ2 test.
Numbers in parenthesis are the numbers of abnormal embryos.
Phenotypes of EIIIA and EIIIB double-null embryos
There was heterogeneity of phenotype among the double-null embryos in the mixed background crosses. About half of the double-null embryos of mixed genetic background showed severe cardiovascular defects by e9.5. These defects included hemorrhage within the embryo (83% of all defective embryos) and anemia due to leakage of blood (Fig. 4A, B, G), shortened posterior, kinked neural tube (5% of all defective embryos) (Fig. 4A) and blistered appearance of the yolk sac (30% of all defective embryos) resulting from separation of endodermal and mesodermal layers (Fig. 4B, J, K). These defects are reminiscent of, but milder than, the defects in FN-null or in FN-receptor, integrin α5-null embryos. By e10.5 about 80% of the double-null embryos showed vascular defects (Fig. 4D, E). These defects included embryonic hemorrhage (100%), dilation of pericardial cavity (50%), and thinned outflow tract (30%) (Fig. 4D). A small number of double-null embryos (about 7%) appeared morphologically normal (compare Fig. 4E and F) but exhibited focal hemorrhage in the head (Fig. 4E, I); the yolk sac vasculature and the heart developed normally in these embryos (data not shown).
Embryonic vascular development in the double-null embryos was analyzed by detecting vessels with antibody specific for the endothelial marker Pecam-1 (Fig. 5; summarized in Table 2). At e9.5, double-heterozygous embryos (Fig. 5A) and some morphologically normal double-null embryos (Fig. 5B) had correctly patterned vasculature with large vessels and a finely patterned vascular plexus in the head and body. In contrast, in severely affected double-null embryos (Fig. 5C) and even in some morphologically normal e9.5 double-nulls (Fig. 5D), there were few and dysmorphic large vessels in the head, and small vessels in the head and body appeared syncytial with endothelial cells forming sheets instead of tubes (Fig. 5C, D, I, J). Interestingly, we observed two kinds of vascular defects in morphologically normal double-nulls. Some of them presented with a syncytial head vasculature (Fig. 5D), these embryos would presumably be dying by e10.5; others developed a normal vascular plexus of small vessels but abnormal patterning of the large head veins, where vessels appeared blunt-ended and discontinuous (Fig. 5E).
Table 2.
Appearance of head vessels1 | ||||||
---|---|---|---|---|---|---|
e9.5 | e10.5 | |||||
Normal | Syncytial2 | Blunt3 | Normal | Syncytial | Blunt | |
Grossly abnormal nulls | 0 | 2 | 0 | 0 | 5* | 1 |
Grossly normal nulls | 2 | 3 | 2 | 2 | 0 | 2 |
Grossly normal hets | 10 | 1 | 0 | 5 | 0 | 0 |
Detected by anti-Pecam-1 antibody staining.
Syncytial refers to the appearance of small vascular plexus in the head;
Blunt refers to the appearance of large head veins.
In addition to these five, two other embryos had unremodeled head vasculature with dilated small vessels and very few large vessels in the head.
Vascular defects in the double-null embryos at e10.5 could also be divided into two groups - the most severely affected embryos had syncytial vasculature with endothelial cells forming sheets instead of tubes (Fig. 5G) and less severely affected, morphologically normal double-null embryos, with abnormally patterned, blunt-ended and constricted head veins (Fig. 5H). It is plausible that one of these constricted vessels could rupture leading to focal hemorrhage in the head.
Extraembryonic vascular defects
Most but not all morphologically abnormal double-null embryos exhibited defects in the development of yolk sac and placental vasculature. Embryos with blistered yolk sacs had unremodeled and dilated yolk sac vessels and a general lack or degeneration of large vessels (Fig. 6A–D and data not shown). About 90% of embryos showing severe intra-embryonic vascular defects also had defective yolk sac vasculature, suggesting that EIIIA and EIIIB splice variants function in embryos and yolk sacs to remodel the initial uniform vascular plexus into a more mature pattern with large and small vessels.
Placental vascularization was also defective in some (~ 50%) of the abnormal double-null embryos (Fig. 6E–H). Starting at e8.5, embryonic vessels invade placenta and by e10.5 form elaborate finger-like projections in the placental labyrinth (Fig. 6E, G). However, in about 50% of the double-null embryos, placental vascularization following the invasion with embryonic vessels was much less extensive (Fig. 6F, H). While vessels did enter the labyrinth layer initially in these embryos, they failed to form extensive projections and branches, suggesting that EIIIA and EIIIB splice variants are important for vascularization of this initially avascular placental layer. Since only about half of the e9.5 and e10.5 abnormal embryos had defects in placental vascularization, aberrant placental development was not the cause or the consequence of embryonic vascular defects, suggesting independent roles for EIIIA and EIIIB in both embryonic and placental vascular development. Similarly, defective yolk sac vasculature was not a cause or a consequence of defective placental angiogenesis, suggesting independent roles for EIIIA and EIIIB splice variants in both yolk sac and placental vascularization. Thus, these different developmental defects in different vascular beds can be uncoupled and appear to be independent consequences of the lack of EIIIA and EIIIB splice variants.
Heart Defects in the EIIIA/EIIIB double-null embryos
Most of the affected double-null embryos had gross morphological heart defects such as edema and thinned or dilated outflow tracts (Figs. 4D, 7A). Some embryos (three out of six morphologically abnormal e10.5 double-nulls analyzed) had defects in cardiac cushion formation (Fig. 7A, Ba and Fig. S2). One of the embryos contained multilayered endothelium in the outflow tract with no evidence of cushion cell differentiation (Fig. 7Ba), another had multiple layers of endothelium in the atrio-ventricular cushions (not shown), while in the third double-null embryo, cushion cells did develop, but were cuboidal in shape and did not express phosphorylated SMAD2 (Fig. S2), suggesting a role for EIIIA and EIIIB splice variants in transformation of endocardial cells into cushion cells.
Vascular smooth muscle cell development in the double-null embryos
Earlier studies had suggested a role for EIIIA in induction of αSMA (Serini et al., 1998). However, our previous studies indicated that, individually, the absence of either EIIIA or EIIIB did not affect expression of αSMA in tumor stroma (Astrof et al., 2004). Specific expression of FN and its splice variants around dorsal aortae in embryos suggested that these splice variants might play a role in the development of aortic vessels during embryogenesis. The most notable difference between dorsal aortae and anterior cardinal veins in e9.5 and e10.5 embryos is the presence of vascular smooth muscle cells expressing αSMA specifically around dorsal aortae but not around anterior cardinal veins (Fig. 7; (Li et al., 2003). To examine smooth muscle cell association with the aortae, e9.5 and e10.5 embryos were stained using both anti-Pecam 1 and anti-αSMA antibodies, and the number, association, and morphology of αSMA-positive cells were assessed. Enumeration of αSMA-positive cells around dorsal aortae at e9.5 indicated that there was a statistically significant difference in the number of αSMA-positive cells closely associated with dorsal aortae in EIIIA/EIIIB-double null embryos compared with their heterozygous littermates (Fig. 8A, B). Both morphologically normal and abnormal double-null embryos showed a decrease in the number of vascular smooth muscle cells (Fig. 8A). By e10.5 most of the dorsal aortae in morphologically abnormal double-null embryos were surrounded by αSMA-positive cells, suggesting that there is only a delay in recruitment or differentiation of these cells in the double-nulls. Interestingly, three of five double-null embryos at e10.5 contained αSMA-positive cells beyond the immediate vicinity of the vessels (Fig. 8C–E), suggesting that there is a defect in migration of αSMA-positive cells to dorsal aortae in the double-null embryos. These e10.5 double-null embryos also had defective association of αSMA-positive cells with the endothelium of dorsal aorta (Fig. 7B, a–d). Instead of being closely opposed to the endothelial lining of the vessel, the αSMA-positive cells were rounded, suggesting a defect in vascular smooth muscle cell spreading along the vessel wall. Taken together, our experiments suggest that EIIIA and EIIIB splice variants function in recruitment, differentiation and associations of aortic αSMA cells to vessels in vivo.
Discussion
The alternative splicing of EIIIA and EIIIB was discovered about twenty years ago (Kornblihtt et al., 1984b; Schwarzbauer et al., 1987) and a myriad of studies that followed attempted to address the functions of EIIIA and EIIIB splice variants in cell culture and in vivo. However, this turned out to be a difficult problem largely because FN is a complex multidomain protein. It is difficult to produce full-length FN in a recombinant form and it is hard to deplete cells or media completely of FN, hampering reconstitution studies. Unexpectedly, mice carrying individual deletions of EIIIB or EIIIA exons were viable and fertile (Fukuda et al 2002; Muro et al, 2003; Tan et al, 2004,), and did not provide insight into why the sequences and patterns of expression of EIIIA and EIIIB are so highly evolutionarily conserved. It is possible that EIIIA and EIIIB are overlapping in function. However, the fact that their sequences are only about 30% identical to each other in a given species argues to some extent against this model. Alternatively, while EIIIA and EIIIB may be important in the same biological process (e.g. blood vessel development), their functions could differ, but the presence of one splice variant is sufficient to support life in the artificial environment of a mouse cage. Lastly, the phenotypes of gene deletions often vary depending on genetic background, and it is possible that unknown genetic factors allowed the survival and function of EIIIA-null or EIIIB-null mice, both of which have been backcrossed to C57BL6/J genetic background.
Analysis of genomes from different phyla have suggested that FN is unique to vertebrates (Whittaker et al, 2006). The expression pattern of FN together with the severe vascular abnormalities in FN-null embryos suggested that FN functions in blood vessel development and may have evolved for that purpose. The alternatively spliced forms of FN containing EIIIA and EIIIB are also expressed around developing vasculature suggesting that they too may function in some aspect of vessel development. Indeed, we found that the absence of both EIIIA and EIIIB exons from FN message resulted in embryonic lethal cardiovascular defects.
The absence of EIIIA and EIIIB gives rise to pleiotropic vascular defects ranging from severe to mild malformations and some progeny survive. We noticed that about 20% of double-null mice were viable and fertile on a mixed 129P2/C57BL6/J background, while on a relatively pure C57BL6/J (six generations of backcrossing) about 50% survived to adulthood, appeared normal and were fertile (unpublished data). In contrast, no adult double-null mice have been observed in 129S4 strain (backcrossed for six generations). Thus the pleiotropic nature of the cardiovascular defects in the EIIIA/EIIIB double-null mice could in part be explained by segregating genetic factors in the mixed 129P2/C57BL6/J population. We have previously reported that the embryonic-lethal phenotype of FN-null embryos is more severe on a 129S4 than a C57BL/6 background (George et al, 1997) and we have mapped a strain-specific genetic modifier affecting the difference (Astrof et al, 2007). It is possible that the same modifier is affecting the phenotype of the EIIIB/EIIIA double-null embryos and this will need to be investigated.
Most of the defective embryos showed various forms of heart defects. The most severely affected embryos displayed heart defects by e9.5. These defects included inflated pericardial cavity, pericardial edema, degenerating linear heart tube, or dilated aortic sac (data not shown). The embryos surviving to e10.5 also had similar defects. Since EIIIA and EIIIB splice variants are expressed in endocardial cells and in cardiac cushion cells, we examined whether there is a defect in the development of cardiac cushions. Three out of the six closely examined e10.5 embryos showed cushion defects, suggesting a role for EIIIA and EIIIB in this epithelial to mesenchymal transition in the heart. It is possible that examination of cardiac malformations in a pure background (129S4 or C57BL6/J) may decrease variability in the phenotype making it more amenable to study.
Not all vascular beds were defective in EIIIA/EIIIB double null mice; for example, small vessels in the yolk sac, head and trunk were syncytial in the severely affected embryos, but endothelial tubes of dorsal aortae and intersomitic vessels formed apparently normally. This could be due to different requirements for EIIIA and EIIIB in blood vessel development in different embryonic compartments. In addition, EIIIA and EIIIB seem to play distinct roles in vascularization of different tissues. For example, in severely affected embryos, the absence of EIIIA and EIIIB in yolk sacs and in the head resulted in defective vascular remodeling while in the placenta, the absence of EIIIA and EIIIB led to defects in angiogenesis (sprouting of the new vessels from the pre-existing ones).
Embryonic vessels in the placenta are derived from allantoic vessels, which invade the placental labyrinth following the attachment of allantois to placenta by e8.5 of development. We did not see any differences in the invasion of the labyrinth layer by embryonic vessels, neither at e8.5 nor at e9.5 (data not shown), however we observed many fewer vessel sprouts in the labyrinth of some e10.5 embryos suggesting that, in the placenta, EIIIA and EIIIB function in vessel sprouting. It is unclear why vascularization of only some placentae was affected. This could be due to genetic differences or stochastic events. In either case, embryonic vascular defects did not arise as a consequence of defective placental vascularization since only about half of the defective embryos exhibited defective placentae. In support of this conclusion, Gcm-1 null embryos, in which placental labyrinth does not have any embryonic blood vessels, do not develop intra-embryonic vascular defects (Anson-Cartwright et al., 2000).
FN-null mutations in mice and zebrafish as well as FN-blocking experiments in frogs showed that the absence of FN affects organ assembly but not specification of precursor cells (George et al., 1993; Marsden and DeSimone, 2001; Marsden and DeSimone, 2003; Trinh and Stainier, 2004). For example, somite, notochord and heart precursors are specified but none of these assemble into proper somites, notochord or heart structures. While the molecular mechanisms of these defects are not completely clear, in both zebrafish and frogs, the absence of FN alters cell polarity leading to defects in polarized cell movements during migration of heart primordia toward the midline in fish or during convergent extension in frogs. Vascular defects in FN-null and EIIIA/EIIIB-null embryos could also be a consequence of defects in endothelial cell polarity resulting in aberrant endothelial tube formation. Small vessels do not form properly in the heads of severely affected EIIIA/EIIIB double-null embryos; instead of distinct vessel tubes, we observed two sheets of endothelial cells that occasionally touch each other forming dilated vessel lumens (very similar to the ones seen in severely affected yolk sacs). Studies of tube formation during the past ten years have shown that lumen formation in epithelial or endothelial systems (and others) requires the establishment of apical (luminal) and basolateral (abluminal) polarity through the biogenesis of apical cell surfaces and exocytosis of vacuoles at the apical membrane (Lubarsky and Krasnow, 2003). It is tempting to speculate that formation of endothelial sheets instead of tubes may be due to a defect in endothelial apical-basolateral polarity in the absence of both EIIIA and EIIIB.
While aortae do form in EIIIA/EIIIB double-null embryos, we noticed a statistically significant difference in the numbers of αSMA+ cells immediately surrounding each dorsal aorta. At e9.5, there were three-fold fewer αSMA+ cells around aortae in the double-null embryos compared with their heterozygous littermates. With the exception of a few embryos that had very few aortic αSMA+ cells, by e10.5 most of the double-null embryos contained αSMA+ cells around their aortae suggesting that there is a delay in recruitment or differentiation of αSMA+ cells in the double-null embryos. Whereas present experiments cannot precisely distinguish between these possibilities, we think that there is a delay in recruitment of these cells since in some e10.5 embryos αSMA+ cells surround the dorsal aortae but a number of others are located a few cell diameters away from the actual vessel. Interestingly, αSMA+ cells around dorsal aortae are derived from paraxial mesodermal precursors that also give rise to somites. These precursors express Pax3 and are seen migrating toward the dorsal aortae from their paraxial locations (Esner et al., 2006). It would be interesting to examine migration of these cells in EIIIA/EIIIB double-null embryos.
Whatever the cellular mechanisms contributing to the vascular defects we describe, it will also be necessary to define the underlying molecular functions of the EIIIA and EIIIB segments. As discussed earlier, this has proven to be difficult in the past but future studies will be given impetus by the evidence for important in vivo functions of these segments. It has been reported that the EIIIA segment can bind to integrins α4β1 and α4β1(Liao et al., 2002) and to the Toll-4 receptor (Okamura et al., 2001), although the functional implications of these bindings have not been elucidated. Fibronectin has also been reported to bind several growth factors involved in angiogenesis; VEGF (Wijelath et al., 2002) and HGF (Rahman et al., 2005). The potential involvement of these various properties in vascular development will need to be investigated.
The existence of the alternatively spliced EIIIA and EIIIB segments of FN has been known for 20 years and the high level of conservation of their sequences and of their tightly regulated patterns of splicing has indicated that they provide some evolutionary conserved function(s). However, in vitro analyses over the past two decades have failed to reveal clear roles for these segments. Our studies demonstrate for the first time that EIIIA and EIIIB-containing splice variants of FN are crucially involved in cardiovascular development. The molecular mechanisms of their functions, as well as elucidation of the individual roles of EIIIA and EIIIB, will await further detailed in vitro and in vivo studies. The mice we report here and cells derived from them will provide valuable reagents for these investigations. The availability of mouse strains showing both embryonic defects and postnatal viability (depending on genetic background) will allow analyses of a variety of developmental, physiological and pathological situations.
Supplementary Material
Acknowledgments
We thank Elizabeth George for the EIIIA targeting construct, probes for Southern blot, pMC-Cre, a cre-expression vector, and advice on generating the EIIIA deletion; Denise Crowley for histology; Kevin Eggan for demonstration and advice on isolation and culturing of ES cells; Adam Lacy-Hulbert and Arjan van der Flier for advice on generating the EIIIA-null allele as well as helpful discussion; Peimin Qi and the MIT transgenic facility for generating chimeric mice; Yueyi Zhang and Rosaria Chiang for immunohistochemical staining; Patrick Stern and Nathan Astrof for discussion and ideas. This research was supported by the National Heart Lung and Blood Institute, NIH (PO1-HL066105 and by the Howard Hughes Medical Institute) and by an ACS Postdoctoral Fellowship to S.A. ROH is an Investigator of the Howard Hughes Medical Institute.
Abbreviations
- FN
fibronectin
- EIIIA,EIIIB
extra fibronectin type III domain A or B
- αSMA
alpha smooth muscle actin
- PECAM
platelet/endothelial cell adhesion molecule
- MEF
mouse embryo fibroblasts
- ES cells
embryonic stem cells
- NEM
N-ethyl maleimide
- PMSF
phenylmethylsulphonyl fluoride
- EDTA
ethylenediaminetetraacetic acid
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- Anson-Cartwright L, Dawson K, Holmyard D, Fisher SJ, Lazzarini RA, Cross JC. The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta. Nat Genet. 2000;25:311–4. doi: 10.1038/77076. [DOI] [PubMed] [Google Scholar]
- Aota S, Nagai T, Yamada KM. Characterization of regions of fibronectin besides the arginine-glycine-aspartic acid sequence required for adhesive function of the cell-binding domain using site-directed mutagenesis. J Biol Chem. 1991;266:15938–43. [PubMed] [Google Scholar]
- Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, Hynes RO. Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol. 2004;24:8662–70. doi: 10.1128/MCB.24.19.8662-8670.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bloom L, Ingham KC, Hynes RO. Fibronectin regulates assembly of actin filaments and focal contacts in cultured cells via the heparin-binding site in repeat III13. Mol Biol Cell. 1999;10:1521–36. doi: 10.1091/mbc.10.5.1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75–85. doi: 10.1002/ijc.10662. [DOI] [PubMed] [Google Scholar]
- Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol. 1989;108:1139–48. doi: 10.1083/jcb.108.3.1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL, Neri D, Zardi L. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002;161:1695–700. doi: 10.1016/S0002-9440(10)64446-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen W, Culp LA. Adhesion mediated by fibronectin's alternatively spliced EDb (EIIIB) and its neighboring type III repeats. Exp Cell Res. 1996;223:9–19. doi: 10.1006/excr.1996.0053. [DOI] [PubMed] [Google Scholar]
- Esner M, Meilhac SM, Relaix F, Nicolas JF, Cossu G, Buckingham ME. Smooth muscle of the dorsal aorta shares a common clonal origin with skeletal muscle of the myotome. Development. 2006;133:737–49. doi: 10.1242/dev.02226. [DOI] [PubMed] [Google Scholar]
- ffrench-Constant C, Hynes RO. Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development. 1989;106:375–88. doi: 10.1242/dev.106.2.375. [DOI] [PubMed] [Google Scholar]
- ffrench-Constant C, Van de Water L, Dvorak HF, Hynes RO. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol. 1989;109:903–14. doi: 10.1083/jcb.109.2.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fukuda T, Yoshida N, Kataoka Y, Manabe R, Mizuno-Horikawa Y, Sato M, Kuriyama K, Yasui N, Sekiguchi K. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 2002;62:5603–10. [PubMed] [Google Scholar]
- George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood. 1997;90:3073–81. [PubMed] [Google Scholar]
- George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993;119:1079–91. doi: 10.1242/dev.119.4.1079. [DOI] [PubMed] [Google Scholar]
- Georges-Labouesse EN, George EL, Rayburn H, Hynes RO. Mesodermal development in mouse embryos mutant for fibronectin. Dev Dyn. 1996;207:145–56. doi: 10.1002/(SICI)1097-0177(199610)207:2<145::AID-AJA3>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
- Glukhova MA, Frid MG, Shekhonin BV, Vasilevskaya TD, Grunwald J, Saginati M, Koteliansky VE. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol. 1989;109:357–66. doi: 10.1083/jcb.109.1.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gu H, Zou YR, Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell. 1993;73:1155–64. doi: 10.1016/0092-8674(93)90644-6. [DOI] [PubMed] [Google Scholar]
- Guan JL, Hynes RO. Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor alpha 4 beta 1. Cell. 1990;60:53–61. doi: 10.1016/0092-8674(90)90715-q. [DOI] [PubMed] [Google Scholar]
- Guan JL, Trevithick JE, Hynes RO. Retroviral expression of alternatively spliced forms of rat fibronectin. J Cell Biol. 1990;110:833–47. doi: 10.1083/jcb.110.3.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hashimoto-Uoshima M, Yan YZ, Schneider G, Aukhil I. The alternatively spliced domains EIIIB and EIIIA of human fibronectin affect cell adhesion and spreading. J Cell Sci. 1997;110(Pt 18):2271–80. doi: 10.1242/jcs.110.18.2271. [DOI] [PubMed] [Google Scholar]
- Hynes RO. Fibronectins. New York: Springer-Verlag; 1990. [Google Scholar]
- Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–87. doi: 10.1016/s0092-8674(02)00971-6. [DOI] [PubMed] [Google Scholar]
- Hynes RO, Zhao Q. The evolution of cell adhesion. J Cell Biol. 2000;150:F89–96. doi: 10.1083/jcb.150.2.f89. [DOI] [PubMed] [Google Scholar]
- Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118:1331–9. doi: 10.1002/ijc.21677. [DOI] [PubMed] [Google Scholar]
- Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. Embo J. 1985;4:1755–9. doi: 10.1002/j.1460-2075.1985.tb03847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kornblihtt AR, Vibe-Pedersen K, Baralle FE. Human fibronectin: cell specific alternative mRNA splicing generates polypeptide chains differing in the number of internal repeats. Nucleic Acids Res. 1984a;12:5853–68. doi: 10.1093/nar/12.14.5853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kornblihtt AR, Vibe-Pedersen K, Baralle FE. Human fibronectin: molecular cloning evidence for two mRNA species differing by an internal segment coding for a structural domain. Embo J. 1984b;3:221–6. doi: 10.1002/j.1460-2075.1984.tb01787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359–69. doi: 10.1016/s0092-8674(00)81280-5. [DOI] [PubMed] [Google Scholar]
- Li S, Wang DZ, Wang Z, Richardson JA, Olson EN. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci U S A. 2003;100:9366–70. doi: 10.1073/pnas.1233635100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liao YF, Gotwals PJ, Koteliansky VE, Sheppard D, Van De Water L. The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem. 2002;277:14467–74. doi: 10.1074/jbc.M201100200. [DOI] [PubMed] [Google Scholar]
- Lubarsky B, Krasnow MA. Tube morphogenesis: making and shaping biological tubes. Cell. 2003;112:19–28. doi: 10.1016/s0092-8674(02)01283-7. [DOI] [PubMed] [Google Scholar]
- Manabe R, Oh-e N, Sekiguchi K. Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem. 1999;274:5919–24. doi: 10.1074/jbc.274.9.5919. [DOI] [PubMed] [Google Scholar]
- Marsden M, DeSimone DW. Regulation of cell polarity, radial intercalation and epiboly in Xenopus: novel roles for integrin and fibronectin. Development. 2001;128:3635–47. doi: 10.1242/dev.128.18.3635. [DOI] [PubMed] [Google Scholar]
- Marsden M, DeSimone DW. Integrin-ECM interactions regulate cadherin-dependent cell adhesion and are required for convergent extension in Xenopus. Curr Biol. 2003;13:1182–91. doi: 10.1016/s0960-9822(03)00433-0. [DOI] [PubMed] [Google Scholar]
- Matter CM, Schuler PK, Alessi P, Meier P, Ricci R, Zhang D, Halin C, Castellani P, Zardi L, Hofer CK, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95:1225–33. doi: 10.1161/01.RES.0000150373.15149.ff. [DOI] [PubMed] [Google Scholar]
- Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol. 2003;162:149–60. doi: 10.1083/jcb.200212079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nagy AGM, Vintersten K, Behringer R. Manipulating the Mouse Embryo: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Laboratories Press; 2003. [Google Scholar]
- Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711–6. [PubMed] [Google Scholar]
- Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF., 3rd The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276:10229–33. doi: 10.1074/jbc.M100099200. [DOI] [PubMed] [Google Scholar]
- Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J Biol Chem. 1989;264:10331–4. [PubMed] [Google Scholar]
- Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861–3. doi: 10.1242/jcs.00059. [DOI] [PubMed] [Google Scholar]
- Peters JH, Chen GE, Hynes RO. Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes Commun. 1996;4:127–48. doi: 10.3109/15419069609010767. [DOI] [PubMed] [Google Scholar]
- Peters JH, Ginsberg MH, Case CM, Cochrane CG. Release of soluble fibronectin containing an extra type III domain (ED1) during acute pulmonary injury mediated by oxidants or leukocytes in vivo. Am Rev Respir Dis. 1988;138:167–74. doi: 10.1164/ajrccm/138.1.167. [DOI] [PubMed] [Google Scholar]
- Peters JH, Hynes RO. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes Commun. 1996;4:103–25. doi: 10.3109/15419069609010766. [DOI] [PubMed] [Google Scholar]
- Rahman S, Patel Y, Murray J, Patel KV, Sumathipala R, Sobel M, Wijelath ES. Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol. 2005;6:8. doi: 10.1186/1471-2121-6-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol. 1995;11:549–99. doi: 10.1146/annurev.cb.11.110195.003001. [DOI] [PubMed] [Google Scholar]
- Schwarzbauer JE, Patel RS, Fonda D, Hynes RO. Multiple sites of alternative splicing of the rat fibronectin gene transcript. Embo J. 1987;6:2573–80. doi: 10.1002/j.1460-2075.1987.tb02547.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Senger DR, Destree AT, Hynes RO. Complex regulation of fibronectin synthesis by cells in culture. Am J Physiol. 1983;245:C144–50. doi: 10.1152/ajpcell.1983.245.1.C144. [DOI] [PubMed] [Google Scholar]
- Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol. 1998;142:873–81. doi: 10.1083/jcb.142.3.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shekhonin BV, Guriev SB, Irgashev SB, Koteliansky VE. Immunofluorescent identification of fibronectin and fibrinogen/fibrin in experimental myocardial infarction. J Mol Cell Cardiol. 1990;22:533–41. doi: 10.1016/0022-2828(90)90955-2. [DOI] [PubMed] [Google Scholar]
- Tan MH, Sun Z, Opitz SL, Schmidt TE, Peters JH, George EL. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. 2004;104:11–8. doi: 10.1182/blood-2003-09-3363. [DOI] [PubMed] [Google Scholar]
- Trachsel E, Kaspar M, Bootz F, Detmar M, Neri D. A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation in vivo. J Invest Dermatol. 2006 doi: 10.1038/sj.jid.5700653. [DOI] [PubMed] [Google Scholar]
- Trinh LA, Stainier DY. Fibronectin regulates epithelial organization during myocardial migration in zebrafish. Dev Cell. 2004;6:371–82. doi: 10.1016/s1534-5807(04)00063-2. [DOI] [PubMed] [Google Scholar]
- Whittaker CA, Bergeron KF, Whittle J, Brandhorst BP, Burke RD, Hynes RO. The echinoderm adhesome. Dev Biol. 2006;300:252–66. doi: 10.1016/j.ydbio.2006.07.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wierzbicka-Patynowski I, Schwarzbauer JE. The ins and outs of fibronectin matrix assembly. J Cell Sci. 2003;116:3269–76. doi: 10.1242/jcs.00670. [DOI] [PubMed] [Google Scholar]
- Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K, Aziz S, Cardona C, Hammond WP, Savidge GF, et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res. 2002;91:25–31. doi: 10.1161/01.res.0000026420.22406.79. [DOI] [PubMed] [Google Scholar]
- Xia P, Culp LA. Adhesion activity in fibronectin's alternatively spliced domain EDa (EIIIA) and its neighboring type III repeats: oncogene-dependent regulation. Exp Cell Res. 1994;213:253–65. doi: 10.1006/excr.1994.1197. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.